» Articles » PMID: 35392643

The Inhibitory Effect and Mechanism of Volatile Oil on Gastric Cancer

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

volatile oil (FAVO) has a good inhibitory activity on gastric cancer cell proliferation, but the mechanism of action is not yet clear. In this study, we tested the antigastric cancer efficacy and mechanism of FAVO using both and models. The results showed that FAVO effectively inhibited the proliferation, migration, and invasion of human gastric cancer SGC-7901 cells, the formation of small tubules of human umbilical vein endothelial cells as well as zebrafish intersegmental vessel and intestinal vein angiogenesis. experiments showed that FAVO significantly delayed the growth of SGC-7901 tumor-bearing nude mice and induced higher serum IL-2 and IFN- and reduced serum IL-6. Western blot results showed that FAVO reduced the expression of HIF-2, VEGF, VEGFR2, P-VEGFR2, Akt, and P-Akt in SGC-7901 cells with CoCl induced hypoxia. We further clarified the main chemical components of FAVO through GC-MS analysis. In summary, FAVO may inhibit tumor growth and angiogenesis via inhibiting the HIF-2/VEGF signaling pathway.

References
1.
Wu D, Potluri N, Lu J, Kim Y, Rastinejad F . Structural integration in hypoxia-inducible factors. Nature. 2015; 524(7565):303-8. DOI: 10.1038/nature14883. View

2.
Cho H, Du X, Rizzi J, Liberzon E, Chakraborty A, Gao W . On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature. 2016; 539(7627):107-111. PMC: 5499381. DOI: 10.1038/nature19795. View

3.
Rios-Navarro C, Hueso L, Diaz A, Marcos-Garces V, Bonanad C, Ruiz-Sauri A . Role of antiangiogenic VEGF-Ab in angiogenesis and systolic function after reperfused myocardial infarction. Rev Esp Cardiol (Engl Ed). 2020; 74(2):131-139. DOI: 10.1016/j.rec.2020.03.013. View

4.
Utegenova G, Pallister K, Kushnarenko S, Ozek G, Ozek T, Abidkulova K . Chemical Composition and Antibacterial Activity of Essential Oils from L. Species against Methicillin-Resistant . Molecules. 2018; 23(7). PMC: 6099696. DOI: 10.3390/molecules23071679. View

5.
Lopes J, Fisher J, Flick H, Wang C, Sun L, Ernstoff M . ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020; 8(1). PMC: 7204809. DOI: 10.1136/jitc-2020-000673. View